Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (400)	3/7/2000 11:06:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1169

today from XNVA, no comments on efficacy.... biz.yahoo.com "The Phase IIa study involving XR9576 and paclitaxel in 12 ovarian patients, which has now been completed, confirmed the positive interim pharmacokinetic results for this trial, which were announced in November 1999. The study shows that paclitaxel can be administered at the full normal dose with XR9576 as a single administration. The study was carried out at The Royal Surrey County Hospital, Guildford, UK, in patients with second line ovarian cancer recurring more than 6 months after previous treatment, who had previously been treated with a variety of cytotoxic drugs, including paclitaxel and platinum drugs. A number of patients in the study are continuing on therapy with XR9576 and paclitaxel and these patients are expected to complete their treatment by mid 2000. The outcome of the study indicates that XR9576 was well tolerated when administered with paclitaxel, and caused no significant drug interaction. Patients received paclitaxel at the standard dose of 175mg/m squared, with a single intravenous XR9576 dose of 150mg 2 hours prior to administration of paclitaxel."